AMARIN CORP PLC\UK Deferred Tax Assets, Operating Loss Carryforwards
AMARIN CORP PLC\UK (AMRN) had Deferred Tax Assets, Operating Loss Carryforwards of $164.93 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $164.93M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $166.41M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $154.09M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $136.86M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $164.93M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $166.41M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $154.09M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $136.86M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $127.38M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $125.86M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $118.22M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $119.36M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $110.72M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $95.18M 10-K · filed 2018-02-27 | $88.34M 10-K · filed 2017-03-01 |
| 2015-12-31 | $89.00M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $80.10M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $85.72M 10-K · filed 2015-03-03 | |
| 2012-12-31 | $55.09M 10-K · filed 2014-02-27 | |
| 2011-12-31 | $32.84M 10-K · filed 2013-02-28 | |
| 2010-12-31 | $27.17M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |